Study S000237

A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01621178
Acronym: AWARD-7
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 577
Start: 2012-07
Primary completion: 2016-06
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: DRUG:Dulaglutide; DRUG:Insulin glargine; DRUG:Insulin lispro
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:H9X-MC-GBDX; EUDRACT_NUMBER:2012-000829-44

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline, 26 Weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT01621178; registry reference DERIVED:39963952
R0017387	Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Tuttle KR, The lancet. Diabetes & endocrinology	2018	Randomized trial	PMID 29910024 DOI	cites ClinicalTrials.gov:NCT01621178; registry reference DERIVED:29910024